Combustion Integrated Rack

NASA Astronaut Available for Interviews Prior to Space Station Mission

Retrieved on: 
Dienstag, Februar 20, 2024

WASHINGTON, Feb. 20, 2024 /PRNewswire/ -- NASA astronaut Tracy C. Dyson is available in limited opportunities to discuss her mission beginning at 8 a.m. EST on Monday, Feb. 26.

Key Points: 
  • WASHINGTON, Feb. 20, 2024 /PRNewswire/ -- NASA astronaut Tracy C. Dyson is available in limited opportunities to discuss her mission beginning at 8 a.m. EST on Monday, Feb. 26.
  • The interviews will take place ahead of Dyson launching to the International Space Station in March.
  • The virtual interviews will stream live on NASA+ , NASA Television, and the agency's website .
  • Learn more about International Space Station research and operations at:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/nasa-astronaut-available-for-in...

Northrop Grumman Sends NASA Science, Cargo to International Space Station

Retrieved on: 
Samstag, Februar 19, 2022

The Cygnus spacecraft, which was launched on an Antares rocket, is scheduled to arrive at the space station around 4:35 a.m. on Monday, Feb. 21.

Key Points: 
  • The Cygnus spacecraft, which was launched on an Antares rocket, is scheduled to arrive at the space station around 4:35 a.m. on Monday, Feb. 21.
  • This is Northrop Grumman's 17th contracted resupply mission under the second Commercial Resupply Services contract with NASA.
  • The delivery includes critical materials to support dozens of the more than 250 science and research investigations occurring during NASA's Expedition 66 mission aboard the space station.
  • Get breaking news, images and features from the space station on Instagram , Facebook , and @space_station and @ISS_Research on Twitter.

AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)

Retrieved on: 
Dienstag, Mai 5, 2020

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinanttherapies forgastrointestinal diseases, today announced AzurRx SAS, its wholly-owned subsidiary in France, has received approximately 661,000 Euros ($721,000 US) for its 2019 CIR (French Research Tax Credit).

Key Points: 
  • NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinanttherapies forgastrointestinal diseases, today announced AzurRx SAS, its wholly-owned subsidiary in France, has received approximately 661,000 Euros ($721,000 US) for its 2019 CIR (French Research Tax Credit).
  • Since March including the 2019 CIR, the Company has received approximately $2.52 million in non-dilutive funding in research tax credits from the French government.
  • James Sapirstein, Chief Executive Officer of AzurRx commented, We are very pleased to receive the 2019 CIR and very appreciative of the French governments support, as we originally anticipated that we would receive the 2019 CIR towards the end of the year.
  • The Research Tax Credit (CIR) is a tax incentive provided by the French Government to encourage the growth of businesses' competitiveness by favoring research and development (R&D) and innovative activities.